D3 Bio Completes Series A+ Round to Advance Innovative Oncology Pipeline
SHANGHAI, April 8, 2024 /PRNewswire/ — D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs announces its closing of Series A+ financing round led by Medicxi, a leading European life sciences investment firm. D3 Bio’s existing investors, Matrix Partners China and WuXi AppTec’s Corporate Venture Fund also […]